Previously, Aicher worked at National Genetics Institute (NGI), a wholly owned subsidiary of Laboratory Corporation of America (LabCorp), as CEO as well as served various executive leadership roles at Central Diagnostics Laboratory.

Omicia CEO Mike Aicher said to reach the full potential for genomic testing, the analysis of complex sequence data must be simplified so that the information can be integrated with other routine tests to help diagnose disease and guide treatment decisions.

"Martin and the outstanding Omicia team have built a truly ground-breaking genome interpretation platform with the highest levels of scientific credibility," Aicher added.

"I look forward to leading Omicia as we enter the commercial market to bring researchers and clinicians better tools for translating genomic data into medically actionable information."

Omicia chairman John Stuelpnagel said, "Mike’s deep operational expertise, coupled with the world-class genomics and software engineering team assembled by Martin will help Omicia make genome analysis a more routine part of health care delivery."